Related Experiment Videos
TB vaccines for the World
1TB Research Group, Veterinary Laboratories Agency, Weybridge, Addlestone, Surrey KT15 3NB, UK. r.g.hewinson@vla.defra.gsi.gov.uk
Tuberculosis (Edinburgh, Scotland)
|February 3, 2005
Summary
The 2003 "TB Vaccines for the World" conference marked a pivotal moment in tuberculosis vaccine development, showcasing promising candidates and new clinical trial initiatives. This event serves as a benchmark for future progress in creating effective TB vaccines.
Area of Science:
- Tuberculosis (TB) vaccine research and development.
- Infectious disease epidemiology and control.
- Vaccinology and immunology.
Background:
- The "TB Vaccines for the World" conference in September 2003 convened the global TB vaccine community.
- Key international TB vaccine screening contracts and initiatives were concluding, necessitating a review of progress.
- The conference occurred at a critical juncture, with emerging vaccine candidates and new clinical trial approaches.
Framework:
- The conference provided a first look at promising TB vaccine candidates identified through various animal models.
- It highlighted the initiation of the first Phase I human trial for a novel TB vaccine, MVA85A.
- The launch of the Aeras Global TB Vaccine Foundation signaled a shift towards an industrial pipeline for vaccine development.
Implementation:
- The article reviews the scope of the special edition of Tuberculosis, dedicated to this defining moment.
- It aims to capture the state of TB vaccine development in 2003.
- The content serves as a historical reference point for evaluating future advancements in TB vaccine research.
Implications:
- The 2003 conference and subsequent special issue established a benchmark for measuring progress in TB vaccine development.
- It underscored the need for continued investment and collaborative efforts in combating tuberculosis.
- The insights gained continue to inform strategies for developing effective vaccines against TB.